Author: healthadmin

Researchers are tracking how early exposure to ultra-processed foods can impact health across generations, from a mother’s metabolism to an infant’s developing microbiome. Proposed mechanism linking maternal UPF intake and gut-brain axis disruption. Image taken from López-Yerena, A., Pinto, V., Stella, BM, Yaşar, E., Camafort, M., Vives-Giralt, MQ, Casanovas-Garriga, F., Ruiz-Leon, AM, Estruch, R., and Casas, R. (2025). Unhealthy diets, unhealthy futures: How modern dietary patterns endanger the health of mothers and children. Nutrients, 18(14), 2320. https://www.mdpi.com/2072-6643/18/14/2320 using ChatGPT/OpenAI In a recent review published in a magazine nutrientsThe authors’ group summarized current evidence on how ultra-processed food (UPF) consumption during…

Although many plastic products are only used for minutes or hours, the materials can remain in the environment for decades or even centuries. Researchers are now investigating a different approach: plastics designed to break down on their own when activated. These materials, known as living plastics, contain dormant microorganisms that can degrade the surrounding polymers. In a study published in ACS applicable polymer materialsScientists have developed a version that completely decomposes in six days without producing microplastics. “The realization that traditional plastics last for centuries, while many applications such as packaging are short-lived, led us to wonder if it was…

6 Cohort analysis links elevated baseline p-tau217 to increased 5- and 10-year risk, brings the pre-symptomatic risk model closer and reveals why routine screening is not yet ready. Study: Prognostic value of blood-based P-Tau217 levels on progression to cognitive impairment. Image credit: Lightspring / Shutterstock In a recent study published in American Medical Association JournalResearchers found that baseline concentrations of plasma phosphorylated tau-217 (p-tau217), a blood-based protein biomarker, were associated with risk of future cognitive impairment in cognitively intact older adults. This study combined data from six international cohorts (n = 2,684 participants) and found that higher baseline p-tau217 levels…

For decades, medicine has pursued the simple but elusive goal of getting the right drug to the right place at the right time. New research from the University of Oregon suggests that the timing of regeneration cues may be even more important than previously realized when it comes to healing from injury. The findings suggest a possible explanation for why some regenerative therapies are successful in the lab but perform poorly in the clinic. This means that regenerative therapies may be delivering the right regenerative cues in the wrong order. This study also demonstrates how to precisely control the rate…

A team of researchers at the University of Utah Huntsman Cancer Institute reports that an innovative pathway-targeted therapy may be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease. Dr. Martin McMahon, senior director of preclinical translation at the Huntsman Cancer Institute and professor of dermatology in the United States, evaluated an investigational compound for the drug daraxonelasib. NRAS-Driven melanoma. NRAS- Propulsive melanoma is an aggressive type of skin cancer caused by mutations in the skin. NRAS gene. Daraxonrasib, developed by Revolution Medicines, targets and inhibits RAS, a protein that when…

Cancer treatments such as radiation and chemotherapy work primarily by shredding the DNA of cancer cells so that they can no longer reproduce. However, cancer cells are known to be resilient, often deploying their own internal “repair squads” to repair the damage caused by treatment, continue to proliferate, and eventually become resistant to treatment. Researchers at Wayne State University and Indiana University have developed an innovative approach that has the potential to significantly increase the effectiveness of standard cancer treatments at lower doses and safely by inhibiting cancer’s ability to heal itself. With support from a new grant from the…

Loss of one copy of DNA ligase I (LIG1) Genes of triple negative breast cancer (TNBC) TP53 Mutations confer resistance to chemotherapy, but researchers at Baylor College of Medicine and collaborating institutions identified a vulnerability in these cells and used it to their advantage. The research team has identified the underlying molecular mechanisms of platinum resistance, which can be neutralized with a combination of drugs available to inhibit tumor growth in animal models. Highlights of this work LIG1 Status as a patient stratification factor in current and future clinical trials. This research Molecular cancer therapyJournal of the American Association for…

The Society’s Clinical Practice Guidelines for Testosterone Replacement Therapy in Hypogonadal Men recommend appropriate testing and prescribing practices. 1. Emphasis should be placed on getting an accurate diagnosis from a clinician. Diagnosis of hypogonadism requires confirmation of symptoms of low testosterone and consistently low blood total and free testosterone accurately measured by laboratory tests. The diagnostic approach and definitions are the same for men of any age. Terms such as “age-related,” “late-onset,” and “functional” hypogonadism are difficult to operationally define, blurring the line between treatable disease and normal aging. Hypogonadism…

Researchers at Oregon State University have developed a promising experimental strategy to treat glioblastoma, the most aggressive type of brain tumor. Less than 30% of patients survive 2 years after diagnosis. The study, led by Ole Talatulla, Olena Talatulla, and Yoon Tae-goo from the OSU College of Pharmacy, focuses on two major issues that have long limited treatment for glioblastoma. First, the therapy must cross the blood-brain barrier, a tightly regulated network of cells that protects the central nervous system from substances circulating in the bloodstream. Second, the treatment must reach tumor cells without affecting healthy tissue. Sugar-coated nanoparticles target…

The Trump administration has proposed sweeping changes to Medicare payment policies that would prevent third-party vendors from remotely monitoring patients. Health technology leaders say the changes will significantly disrupt services that help patients manage conditions such as diabetes and high blood pressure. The policy change, included in the draft Medicare physician pay rules announced this week, marks a change that will have far-reaching implications for RPM companies, primary care physicians, hospitals and health systems by eliminating third-party vendors. The Centers for Medicare and Medicaid Services (CMS) on Tuesday announced changes to Medicare Part B payment policies for physicians under the…